Revelation Biosciences, INC 8-K filings

Revelation Biosciences announced that its drug candidate, Gemini, demonstrated statistically significant, dose-dependent increases in the anti-inflammatory protein IL-10 in a Phase 1 clinical study.

Revelation Biosciences has successfully raised approximately $3.8 million by incentivizing warrant holders to exercise their existing warrants at a reduced price.

Revelation Biosciences has received a notification from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Revelation Biosciences announced its financial results for the three and six months ended June 30, 2024, alongside positive Phase 1 clinical trial data for its Gemini program.

Revelation Biosciences has been ordered to pay approximately $7.3 million in a judgment related to a fee dispute with LifeSci Capital LLC, which the company plans to satisfy using existing cash resources.

Revelation Biosciences has adjusted the exercise price of its Class C and D warrants, requiring a temporary manual exercise process until the Depository Trust Corporation system is updated.

Revelation Biosciences held its annual meeting, where shareholders elected directors, approved an increase in shares reserved under the equity incentive plan, and ratified the company's auditor.

Revelation Biosciences announced its financial results for the three months ended March 31, 2024, showing increased cash reserves but a net loss compared to a net gain in the same period last year.

Revelation Biosciences announced its 2023 year-end financial results, highlighted by a $6.2 million public offering, the start of a Phase 1 clinical study for Gemini, and positive preclinical data for acute kidney injury.

Revelation Biosciences presented preclinical data at the 29th International Conference on Advances in Critical Care Nephrology showing that their drug candidate, Gemini, significantly improved kidney function and reduced tissue damage in a rat model of acute kidney injury.

Revelation Biosciences successfully closed a $6.2 million public offering and regained compliance with Nasdaq's minimum bid price requirement.

Revelation Biosciences has released an updated corporate presentation detailing their therapeutic development pipeline, focusing on their Gemini platform for preventing hospital-acquired infections and kidney injuries.

Revelation Biosciences has enacted a 1-for-30 reverse stock split, effective January 25, 2024, to consolidate its outstanding shares.

Revelation Biosciences stockholders have approved a reverse stock split authorization and the ability to adjourn a special meeting if necessary.